- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03786965
Evaluating of Role of Myeloperoxidase in Prediction of Outcomes of Cardiac Surgery Procedures. (MPO-CSP)
November 14, 2021 updated by: Aleksandr Nemkov, St. Petersburg State Pavlov Medical University
The main objection is to investigate molecular biology of myocardial damage during cardiac surgery procedures.
Study Overview
Status
Recruiting
Detailed Description
To assess outcomes after cardiac surgery procedures.
To investigate serum level of myeloperoxidase, morphology of left atrium appendage, to perform genetic analysis and cell biology.
Study Type
Interventional
Enrollment (Anticipated)
2000
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Non-US/Non-Canadian
-
Saint-Petersburg, Non-US/Non-Canadian, Russian Federation, 194358
- Recruiting
- Nikolai Bunenkov
-
Contact:
- Nikolay Bunenkov
- Phone Number: +7-950-028-17-40
- Email: bunenkov2006@gmail.com
-
Contact:
- Vladimir V Komok, Ph.D
- Phone Number: +7 904 632 19 00
- Email: vladimir_komok@mail.ru
-
Principal Investigator:
- Nikolai S Bunenkov
-
Sub-Investigator:
- Aleksey V Sokolov, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- ischemic heart disease with indications for operation
- valve disease with indications for operation
- ischemic heart disease combined with valve disease with indications for operation
Exclusion Criteria:
- patient refusal
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: On-pump CABG.
|
On-pump CABG
|
OTHER: Off-pump CABG.
|
Off-pump CABG
|
OTHER: Pump-assisted CABG.
|
Pump-assisted CABG
|
OTHER: Heart Valve Procedure without CABG.
|
Valve Repair Procedure without CABG (open heart procedure).
|
OTHER: Heart Valve Procedure with CABG.
|
Valve Repair Procedure with CABG (open heart procedure).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Death within 30 days after procedure.
Time Frame: within 30 days after procedure.
|
Death within 30 days after surgical procedure.
|
within 30 days after procedure.
|
Acute myocardial infarction.
Time Frame: within 30 days after procedure.
|
Acute myocardial infarction (ST-changes with troponin I > 10 ng/ml).
|
within 30 days after procedure.
|
Stroke.
Time Frame: within 30 days after procedure.
|
Stroke (MRI changes or corresponding neurologist record).
|
within 30 days after procedure.
|
Arrhythmia
Time Frame: within 30 days after procedure.
|
Any type of arrhythmia including AV-block.
|
within 30 days after procedure.
|
Renal dysfunction.
Time Frame: within 30 days after procedure.
|
Renal dysfunction if serum creatinine greater than 25% of upper reference range.
|
within 30 days after procedure.
|
Infection or febrile.
Time Frame: within 30 days after procedure.
|
Infection or febrile (t> 37 or CRP elevation or long regeneration of surgical wound).
|
within 30 days after procedure.
|
Respiratory dysfunction.
Time Frame: within 30 days after procedure.
|
Respiratory dysfunction (pulmonary ventilation longer than 2 days).
|
within 30 days after procedure.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Alexander Nemkov, PhD, First Saint-Petersburg Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 20, 2018
Primary Completion (ANTICIPATED)
July 20, 2025
Study Completion (ANTICIPATED)
December 20, 2025
Study Registration Dates
First Submitted
December 20, 2018
First Submitted That Met QC Criteria
December 20, 2018
First Posted (ACTUAL)
December 26, 2018
Study Record Updates
Last Update Posted (ACTUAL)
November 16, 2021
Last Update Submitted That Met QC Criteria
November 14, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- №22/18-H
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Individual participant data are confidential.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Heart Disease
-
Genzyme, a Sanofi CompanyTerminatedIschemic Heart Disease | Ischemic Cardiomyopathy | Ischemic Heart FailureBelgium, France, Germany, Italy, Switzerland, United Kingdom
-
University of AlbertaRecruitingCoronary Artery Disease | Stable Ischemic Heart Disease | Beta-blocker TherapyCanada
-
Gerencia de Atención Primaria, MadridServicio Canario de Salud; Avedis Donabedian Research InstituteCompletedIschemic Heart Disease ChronicSpain
-
Michael SekelaCompletedChronic Ischemic Heart DiseaseUnited States
-
Cardiocentro TicinoTerminatedChronic Ischemic Heart DiseaseSwitzerland
-
Rigshospitalet, DenmarkNot yet recruitingChronic Ischemic Heart DiseaseDenmark
-
University of PecsCompleted
-
The University of Texas Health Science Center,...National Heart, Lung, and Blood Institute (NHLBI); Cardiovascular Cell Therapy...CompletedIschemic Cardiomyopathy | Left Ventricular Dysfunction | Angina | Chronic Ischemic Heart DiseaseUnited States
-
Affiliated Hospital to Academy of Military Medical...Ivy Institute of Stem Cells Co. LtdUnknownHeart Failure | Angina | Chronic Ischemic Heart DiseaseChina
-
University of EdinburghUnknown
Clinical Trials on On-pump CABG
-
Assiut UniversityRecruitingCAD - Coronary Artery DiseaseEgypt
-
St. Petersburg State Pavlov Medical UniversityRecruitingIschemic Heart Disease | Coronary Artery Bypass GraftingRussian Federation
-
St. Petersburg State Pavlov Medical UniversityCompletedCoronary Artery Disease | CABG | Ischemic Heart Disease | Ischemic Reperfusion InjuryRussian Federation
-
Bozok UniversityCompletedMyocardial Infarction | Oxidative Stress | Cerebral OxygenationTurkey
-
Centre hospitalier de l'Université de Montréal...Centre de Recherche du Centre Hospitalier de l'Université de MontréalUnknownGraft Failure | Complications Due to Coronary Artery Bypass GraftCanada
-
West China HospitalRecruitingOn-pump Valve Surgery or CABGChina
-
Pinnacle Health Cardiovascular InstituteCompleted
-
University of Sao Paulo General HospitalMount Sinai Hospital, New York; Beneficência Portuguesa de São Paulo; Instituto... and other collaboratorsRecruitingCoronary Artery Disease | Frail ElderlyUnited States, Brazil
-
Population Health Research InstituteCharles University, Czech Republic; Centre hospitalier de l'Université de Montréal... and other collaboratorsCompletedthe Efficacy and Safety of Off-pump CABGCanada, China, Colombia, India, Chile, Argentina, Brazil, Czech Republic, France, Italy, Poland, Turkey, United Kingdom
-
Assiut UniversityManchester University NHS Foundation TrustUnknownCoronary Artery Disease | Aortic Valve DiseaseEgypt